E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis
patients |
|
E.1.1.1 | Medical condition in easily understood language |
Bacterial infection in cystic fibrosis patients |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011762 |
E.1.2 | Term | Cystic fibrosis |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10021860 |
E.1.2 | Term | Infection Pseudomonas aeruginosa |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare as a primary indicator for ease of use the mean cumulative time required to set-up the delivery device (including preparation of the treatment), administer the drug, and clean the delivery device for TIP administered with the T 326 Inhaler with the cumulative time to perform the same activities (including disinfection of the device, where applicable) for the patient’s usual (pre-study prescribed) nebulized, antibiotic treatment for P. aeruginosa. |
|
E.2.2 | Secondary objectives of the trial |
To assess:
-the absolute change in the number of P.aeruginosa colony-forming units in sputum after up to a period of 28days of treatment in each treatment arm
-the frequency and type of microbial contamination of the T-326 Inhaler used to administer TIP after lifetime use(7days of treatment) compared with the contamination of the nebulizer used for the ent’s usual nebulized antibiotic treatment for P.aeruginosa or for any other nebulized medication at baseline(Visit2)and at each visit.
- tolerability and safety of TIPvsTISvscolistimethate over both the on-treatment and off-treatment periods of the study by comparison of adverse event rates, severity, and discontinuation rates
To evaluate:
-the change in the minimum inhibitory concentration of the relevant antibiotic for P. aeruginosa after a period of up to 28days of treatment of TIPvsTISvscolistimethate
-the safety profile of TIPvsTISvscolistimethate in terms of clinical laboratory results and postinhalational bronchospasm |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Provide written informed consent, Health Insurance Portability and Accountability Act (HIPAA) authorization (where applicable), and assent (as appropriate for minors) prior to the performance of any study-related procedure
2.Confirmed diagnosis of CF by one or more of the following tests for CF (current or historic):
•quantitative pilocarpine iontophoresis sweat chloride test of greater than 60 mmol/L or 60 mEq/L
•genotype with identifiable CF-causing mutations on both chromosomes
•a positive newborn screening for CF
•an abnormal nasal transepithelial potential difference characteristic of CF
3.Male and female patients 6 years of age or older at screening (Visit 1)
4.FEV1 at screening (Visit 1) must be at least 25% and less than or equal to 90% of normal predicted values for age, sex, and height based on the NHANES III values (Hankinson et al 1999) for patients 18 years of age or greater, and based on values from Wang (Wang et al 1993) for patients less than 18 years of age. Please refer to Appendix 4 for the relevant equations.
5.Documented use of any of the inhaled antibiotics to treat chronic P. aeruginosa infection based on local practice:
•TIS, colistimethate, or TIP for at least 1 cycle (4 weeks on treatment followed by 4 weeks off treatment) within the last 6 months or
•colistimethate continuous use for at least 8 weeks within the last 6 months
This cycle of treatment (or continuous colistimethate treatment period) is in addition to the treatment cycle during which the subject is being screened.
6.P. aeruginosa must be present in a sputum or deep cough throat swab culture or bronchoalveolar lavage (BAL) (only for BAL a threshold level of 10^3 CFU/mL is required) within 6 months prior to screening and in the sputum or deep cough throat swab culture at screening or rescreening (Visit 1)
7.Judged by the investigator to be able to use the dry powder inhaler successfully
8.Clinically stable in the opinion of the investigator
|
|
E.4 | Principal exclusion criteria |
1.History of sputum culture or deep cough throat swab (or BAL) culture yielding Burkholderia cenocepacia complex within 2 years prior to screening or sputum culture yielding B. cenocepacia complex at screening (Visit 1)
2.Hemoptysis more than approx. 60 mL at any time within 30 days prior to screening
3.History of hearing loss or chronic tinnitus deemed clinically significant by the investigator
4.Serum creatinine 176.8 μmol/L (2 mg/dL) or greater, blood urea nitrogen (BUN) 14.28 μmol/L (40 mg/dL) or greater or an abnormal urinalysis defined as 2+ or greater proteinuria at screening (Visit 1)
5.Known local or systemic hypersensitivity to aminoglycosides
6.Regularly receiving more than 1 class of inhaled antipseudomonal antibiotic. During the study, inhaled antipseudomonal antibiotics are not allowed other than the antipseudomonal antibiotic the patient is using at the time of entrance into the study.
7.Use of systemic antipseudomonal antibiotics within 28 days prior to study medication administration (Visit 2)
8.For patients on colistimethate: current use of cautioned concomitant medications as indicated in the prescribing information, including aminoglycosides, polymixins, curariform muscle relaxants (e.g. tubocurarine), ether, succinylcholine, gallamine, decamethonium, and sodium citrate, at screening
9.Use of loop diuretics within 7 days prior to study medication administration (Visit 2)
10.Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening (Visit 1)
11.Signs and symptoms of acute pulmonary disease, e.g. pneumonia, pneumothorax
12.Body mass index less than 12 kg/m2
13.History of malignancy of any organ system, treated or untreated
14.Clinically significant laboratory abnormalities (not associated with the study indication) at screening (Visit 1)
15.Clinically significant conditions or findings at screening (Visit 1) that might interfere with the accurate and valid assessment of this study
16.Patients or caregivers who are considered potentially unreliable or considered unlikely to be compliant within the trial
17.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
18.Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, unless they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method.
•Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge, or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
•Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study treatment. Effective contraception methods are defined in the full protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time required to administer study treatment including device set-up, administration, and device breakdown and cleaning |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
* Microbial contamination of delivery device: P. aeruginosa and other pathogens
* Adverse event (AE) rates, severity, and discontinuation rates
* MIC of antibiotics from patients’ specimens (specific for P. aeruginosa)
* Hospitalizations for respiratory-related AE
* Clinical laboratory results and post-inhalational bronchospasm |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Refer to assess schedule in full protocol for the timepoint for each assessment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Ease of use / time spent on treatment |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Nebulised tobramycin, nebulised colistin |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Spain |
Switzerland |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 20 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 20 |